Skip to main content
. 2009 Mar 9;119(4):954–963. doi: 10.1172/JCI34015

Figure 2. SOX9 decreases the proliferation of melanoma cells.

Figure 2

(A) B16/F10 murine melanoma cells were cotransfected with a puromycin resistance vector and either an empty vector (Control) or the SOX9 cDNA (SOX9) and were grown in medium containing puromycin for 15 days. Upper panel: Macroscopic view of the proliferative clones. Middle panels: The same clones at a magnification of ×10. An immunoblot of proteins extracted from those cells using antibodies against SOX9 and GAPDH is shown. (B) A375 human melanoma cells were cotransfected with a puromycin resistance vector and with either an empty vector or the SOX9 cDNA and were grown in medium containing puromycin for 15 days. Upper panel: Macroscopic view of the proliferative clones. Middle panels: The same clones at a magnification of ×10. An immunoblot of proteins extracted from those cells using antibodies against SOX9 and GAPDH is shown. (C) Relative proliferation of SOX9-transfected cells compared with the control for B16/F10, SK-Mel28, A375, and Mel Juso melanoma cell lines. *P < 0.001. (D) SOX9 induces melanoma cell arrest in the G1 phase. B16/F10 and A375 melanoma cells were transduced with SOX9 lentivirus or with GFP lentivirus as a control and then were selected with blasticidin. After 5 days, the cells were stained with propidium iodide, and the cell cycle was studied using FACS analysis. Percentages of cells in G1 are indicated. G1/(S + G2), ratio of cells in G1 to cells in S plus G2.